BioSpace News Archive

Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs, today announced the first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi

E25Bio, innovators of rapid diagnostics and digital health platforms, announced today that Prashant Chouta has been named chief executive officer. “We are thrilled to welcome Prashant to E25Bio. Prashant comes to the team with a history of success at some of the largest companies in the world. His leadership will undoubtedly help guide E25Bio into its next phase and beyond as it looks to revolutionize pandemic respon

Tetra Bio-Pharma Inc. today announces that it has completed the divestiture of Lumiera Health Innovation Inc. (“Lumiera”), its subsidiary, to Mondias Natural Products Inc. (TSXV: NHP) (“Mondias ") as previously announced.

How effective is mouthwash in preventing the spread of coronavirus? Independent lab analysis conducted at MRIGlobal’s accredited in vitro diagnostics laboratory for Rowpar Pharmaceuticals revealed promising findings.

Strive Health, a national innovator in value-based kidney care, announced that it has partnered with nearly 200 physicians and advanced practitioners from 20 nephrology groups across several states to participate in Medicare’s Comprehensive Kidney Care Contracting options of the Kidney Care Choices model.

Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available. This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), and Longboard Pharmaceuticals, Inc., today announced the launch of Longboard Pharmaceuticals and the completion of a $56 million financing led by Farallon Capital Management, LLC, and other top tier healthcare investors,

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4th.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of Pharmaceutical Scientists (AAPS) 2020 PharmSci 360 conference, held virtually this year from October 26 – November 5, 2020.

Neogen Corporation (Nasdaq: NEOG) today announced the launch of Igenity® Feeder, a DNA tool designed to assist cattle producers in the stocker and backgrounder phase to rank and manage feeder cattle according to their genetic potential for carcass traits.